DOCSLIB.ORG

HPV: Here, There, Everywhere Denise Rizzolo, Phd, PA-C HPV Overview

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HPV: Here, There, Everywhere Denise Rizzolo, Phd, PA-C HPV Overview HPV: Here, There, Everywhere Denise Rizzolo, PhD, PA-C HPV Overview • Human papillomavirus (HPV) is the most common sexually transmitted infection (STI). • According to the CDC the prevalence of genital infection with any HPV type was 42.5% among United States adults aged 18–59 years during 2013–2014. • The CDC states that HPV is so common that nearly all men and women who have sex will get it at some point in their lives. • However, many infections remain asymptomatic and resolve spontaneously. HPV Virology • Papillomavirus • Infection limited to basal cells of stratified epithelium. • Infects epithelial tissues through micro-abrasions that expose portions of the basement membrane. • HPV lesions are thought to arise from the proliferation of infected basal keratinocytes. Oncogenic Strains of HPV • 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82 • Probable oncogenic strains: 26, 53, 66, 73, 822 HPV as Causative Agent in… • Anal Cancer • Cervical Cancer • Penile Cancer • Vaginal/Vulvar Cancer • Recurrent Respiratory Papillomatosis* • *Caused most commonly by HPV types 6 + 11 (non-oncogenic) and rarely by HPV types 16/18 The History of HPV Viruses as Emerging Cause of Cancer • As early as 1842 an association was found between sexual activity and cervical cancer • By the 1990 a definitive link between HPV and cancer was determined • What about HPV and Head and Neck Cancer? • 1983 researchers found HPV structural proteins via immunohistochemistry in 6 out of 8 oral squamous cell carcinoma HPV and Oral Cancer—The stats • HPV has been detected in 45% to 90% of head and neck squamous cell carcinomas (HNSCC), most commonly in the lingual and palatine tonsils or base of the tongue. • Incidence rates of HPV-positive oropharyngeal cancer have been increasing among white men and women. Age is usually 10 years younger than that of cancer of the oral cavity; roughly seen as early as 40. • The age at sexual debut is decreasing with oral sex being performed more by men and women that are aged 30 to 49 years compared to older generations. Clinical Case #1 • HPI: A 42 year old Caucasian female presents to your office stating he was referred by his dentist for a tonsillar lesion. She has no significant past medical history and is currently on no medications. • Social & Sexual Hx: She is married with one child. Sexual history is not disclosed. She denies alcohol or smoking tobacco history, but does admit to daily marijuana use for the past 10 years. • PE & Diagnostic Testing: Results of a thorough PE and laboratory evaluation are normal except for a 1.5 cm tonsillar lesion. Biopsy reveals a well- differentiated squamous cell carcinoma, HPV positive. What is the most likely causative strain of the HPV positive squamous cell carcinoma in our case study? A. HPV – 2 B. HPV – 6 C. HPV – 16 D. HPV - 18 HPVHigh Virology Risk Types: and Oncogenesis • 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82 Low Risk Types: • 6, 11, 40, 42, 43, 44, 53, 54, 61, 72, 81 • Associated with about 85 to 95% of HPV- HPV-16 Positive oropharyngeal cancers. • Verruca vulgaris (occur on lips, hard palate, HPV-2 or HPV-4 and gingiva) • Condyloma acuminata (occur as genital warts HPV -6 or HPV – 11 or in the oral mucosa. Commonly found on keratinized mucosa.) ❑ History of sexual activity at a young age ❑ Having multiple sexual partners ❑ History of genital warts Researchers conducted a study in ❑ History of oral sex which they stratified risk factors ❑ History of oral and anal contact according to HPV-16 tumor status ❑ History of marijuana use and found that HPV-16 positive ❑ HIV infection tumors were associated strongly with specific sexual behaviors and marijuana smoking – not with tobacco smoking, alcohol, or poor RISK FACTORS oral hygiene. TRUE or FALSE? The physical exam of a patient with known HPV-positive oral squamous cell carcinoma is typically unremarkable? Signs and Symptoms *Some patients ❑ Persistent sore throat may have no ❑ Non-healing sore in mouth ❑ Earaches signs or ❑ Hoarseness symptoms!* ❑ Enlarges lymph nodes ❑ Pain with swallowing ❑ Unexplained weight loss Physical Exam Findings • High risk clinical presentations: • Sharply defined, leukoplakic lesions (especially those > 1 centimeter in size) • Non-homogenous or mixed red-white lesions • Erythroplakic lesions • Areas of persistent ulceration and indurated lesions Clinical Case #2 • HPI: A 45 year old Hispanic female with PMH of anxiety and seasonal allergies who requests screening for oral HPV • FH: Mother has type 2 diabetes and HTN, Father with high cholesterol • Meds: Valium PRN, OTC antihistamines and nasal corticosteroid spray for seasonal allergies • Social & Sexual Hx: She is divorced, but recently started dating. She has two children. She was monogamous with her husband of 16 years and has not been sexually active since her divorce 1 year ago. She used oral birth control pills as contraception during her marriage. She denies alcohol or smoking tobacco history. Clinical Case #2 • ROS: She denies any suggestive symptoms of oral cancer or HPV, such as persistent sore throat, hoarse voice, oral ulcer or sore that does not heal within 2-3 weeks, dysphagia, pain when chewing, ear pain, or a painless lump on the outside of the neck. • Screenings: Her last dental exam was 5 months ago, no issues. Last PAP 1 year ago, normal. • PE: Overall unremarkable. The oral cavity is thoroughly examined and found to be free of any suspicious lesions. Is there a test to find out if I have oral HPV? Screening for HPV……….. Of the following statements, which one is TRUE? A. Saliva can be used for accurate HPV detection and genotyping PCR to detect the presence of HPV DNA B. Viral antigen detection through blood is a simple way to detect HPV C. Tissue fluorescence visualization is a widely used tool for early detection D. There is no FDA-approved test to diagnose HPV in the mouth or throat Screening for HPV Oral HPV Testing Pitfalls • Acetic staining: May become diluted with saliva, detects trauma • Rinsing: May be positive, but does not indicate where the lesion is • Swab: Must brush non keratinized surface such as buccal mucosa, the vestibule, the floor of the mouth, the border of the tongue (until the oropharynx), under the surface of the tongue. **Keratinized surfaces are resistant to collection) • Biopsy of the lesion is most accurate Prognosis and Treatment Options • Prognosis depends on : • The stage and grade of cancer • Location of tumor • Association of tumor with HPV • Treatment options depend on: • Stage and grade of cancer • Location of tumor • Maintaining patient speech and swallowing functions • General health of patient Staging Stage 0 (Carcinoma in Situ): Abnormal cells found in lining of oropharynx Stage I: Cancer is 2 cm or smaller and found in oropharynx only Stage II: Cancer is larger than 2 cm but not larger than 4 cm and is found in oropharynx only Stage III: Cancer is either ▪ 4 cm or smaller, spread to one lymph node on same side and node is 3 cm or smaller, or; ▪ larger than 4 cm, spread to epiglottis, spread to one lymph node on same side and node is 3 cm or smaller Stage IV: ▪ IVA: Cancer has spread to larynx, front part of roof of mouth, lower jaw or muscles that move the Stagingtongue or are used for chewing. Cancer has spread to one lymph node on same side and is 3 cm or smaller, or: ▪ Cancer has spread to one lymph node on the same side, lymph node is larger than 3 cm but not larger than 6 cm, and one of following is true: ▪ Tumor in oropharynx is any size and may have spread to epiglottis, or: ▪ Tumor has spread to larynx, front part of roof of mouth, lower jaw, or muscles that move the tongue or are used for chewing ▪ IVB: ▪ Tumor surrounds the carotid artery or has spread to the muscle that opens the jaw, the bone attached to the muscles that move the jaw, nasopharynx, or base of skull. Spread to one or more lymph nodes which can be any size, or: ▪ Tumor may be any size and has spread to one or more lymph nodes that are larger than 6 cm ▪ IVC: Tumor may be any size and has spread beyond the oropharynx to other parts of the body such as the lung, bone or liver. Treatment is stage dependent ❑Surgery ❑Radiation Therapy ❑Chemotherapy Stage I and II: ❑Radiation may be preferred where functional deficit will be great, such as the tongue or base of tonsil ❑Surgery may be preferred where functional deficit will be minimal such as tonsillar pillar Treatment Treatment Stage III: ❑Combination of surgery with postoperative radiation or chemoradiation therapy ❑Radiation therapy for patients with cancer of the tonsil ❑Chemoradiation therapy Treatment Stage IV: ❑ Combination of surgery with postoperative radiation therapy plus chemotherapy in high risk patients ❑ Radiation therapy alone for patients with stage IVA cancer of tonsil that does not deeply invade the tongue base Stage Lip Tongue Floor of Mouth Oropharynx and Tonsils I 96% 71% 73% 56% II 83% 59% 60% 58% III 57% 47% 36% 55% IV 48% 37% 30% 43% Five Year Survival Rate for Oropharyngeal Cancer Prognosis for HPV positive OSCC HPV positive OSCC is associated with a significant overall survival rate when compared to patients with HPV negative tumors. Various studies reveal statistics between 40% and 50% increased overall survival rate. Who is talking about Oral HPV with our patients ??? The Dentist ? The Family Practice Provider? HPV Health Literacy • Focus group of 33 dentists was done in 2016 • HPV Infection • Most knew it was a sexually transmitted infection – but only a few knew which types were virulent • HPV Vaccine • Few discussed with patients or new the strains it covered.
Load more

Recommended publications
  • Family Practice
    THE JOURNAL OF FAMILY PRACTICE Michael E. Pichichero, MD Who should get Department of Microbiology and Immunology, Pediatrics, the HPV vaccine? and Medicine, University of Rochester Medical Center, Elmwood Pediatric Group, Latest recommendations from ACIP and others Rochester, NY Practice recommendations have not started sexual activity—are the • Consider recommending HPV vaccine for primary targets of immunization. How- 11- and 12-year-old girls in your practice, ever, the US Food and Drug Administra- before sexual activity puts them at risk tion also approved the use of Gardasil of viral infection (A). The FDA has also for girls as young as 9. Girls this age may approved the HPV vaccine for women require other vaccines, such as meningo- up to 26 years of age. ® Dowdencoccal conjugate Health and tetanus-diphtheria- Media acellular pertussis, and experience thus • If women older than 26 years ask to be far indicates no negative immune effects vaccinated, make sureCopyright they understandFor personalwith co-administration use only of vaccines.1,2 it is an off-label use for them (A). According to one study, vaccination Strength of recommendation (SOR) of the entire US population of 12-year-old A Good-quality patient-oriented evidence girls would prevent more than 200,000 B Inconsistent or limited-quality patient-oriented evidence C Consensus, usual practice, opinion, disease-oriented HPV infections, 100,000 abnormal Pap IN THiS ARTiCLE evidence, case series tests, and 3300 cases of cervical cancer.3 z How vaccination Parental as well as health care provider resexual adolescent girls and acceptance of HPV vaccines for adoles- prevents cervical sexually active women can now cents will be critical to the success of the cancer Plower their lifetime risk of cervical vaccination effort (see “What makes FPs Page 199 cancer, thanks to a newly available quad- recommend the HPV vaccine” on page rivalent vaccine (Gardasil) directed at hu- 201).4 z How HPV infection man papillomavirus (HPV).
    [Show full text]
  • Anal Cytology in Women with Cervical Intraepithelial Or Invasive Cancer
    ORIGINAL ARTICLE J Bras Patol Med Lab, v. 51, n. 5, p. 315-322, October 2015 Anal cytology in women with cervical intraepithelial or invasive cancer: interobserver agreement Citologia anal em mulheres com neoplasia intraepitelial ou invasiva cervical: concordância interobservadores 10.5935/1676-2444.20150051 Sandra A. Heráclio1; Fátima Regina G. Pinto2; Kristiane Cahen2; Letícia Katz2; Alex Sandro R. Souza1, 3 1. Instituto de Medicina Integral Professor Fernando Figueira (Imip). 2. Laboratório Central de Saúde Pública de Pernambuco (Lacen-PE). 3. Universidade Federal de Pernambuco (UFPE). ABSTRACT Introduction: Incidence rates of anal cancer have been rising worldwide in the last 20 years. Due to embryological, histological and immunohistochemical similarities between the anal canal and the cervix, routine screening with anal cytology for precursor lesions in high-risk groups has been adopted. Objective: To determine interobserver agreement for the diagnosis of anal neoplasia by anal cytology. Material and methods: A cross-sectional observational study was conducted in 324 women with cervical intraepithelial or invasive cancers, for screening of anal cancer, from December 2008 to June 2009. Three hundred twenty-four cytological samples were analyzed by three cytopathologists. Cytological evaluation was based on the revised Bethesda terminology; samples were also classified into negative and positive for atypical cells. We calculated the kappa statistic with 95% confidence interval (95% CI) to assess agreement among the three cytopathologists. Results: Interobserver agreement in the five categories of the Bethesda terminology was moderate (kappa for multiple raters: 0.6). Agreement among cytopathologists 1, 2 and 3 with a consensus diagnosis was strong (kappa: 0.71, 0.85 and 0.82, respectively).
    [Show full text]
  • Human Papillomavirus (HPV) and Cervical Cancer: an Update on Prevention Strategies Script August 9, 2005
    Human Papillomavirus (HPV) and Cervical Cancer: An Update on Prevention Strategies Script August 9, 2005 [1]DANIELS Hello and welcome to “Human Papillomavirus (HPV) and Cervical Cancer: An Update on Prevention Strategies.” I’m Kysa Daniels, your moderator for this program, which is originating from the Centers for Disease Control and Prevention in Atlanta, Georgia. In this Webcast, we’ll be discussing genital human papillomavirus (HPV) infection, a sexually transmitted disease. This is an extremely common infection of growing concern to both the public and to health care providers. Our focus today is - an update on the natural history of HPV infection, - the association of different HPV types with various clinical manifestations, - HPV transmission, and... - methods for HPV and cervical cancer prevention. Before we introduce our panelists, let’s hear from CDC Director, Dr. Julie Gerberding. DR. JULIE GERBERDING: Hello! I am Dr. Julie Gerberding, Director of the Centers for Disease Control and Prevention. Thanks for joining us for this very important webcast on Human Papilloma Virus. Genital infection with HPV is the most common sexually transmitted infection in the United States. About 20 million Americans are currently infected with the virus, and about 6.2 million people become newly infected each year. Most infections cause no clinical problems and go away on their own without treatment. But some infections lead to genital warts in men and women, and cervical cancer in women. Although a vaccine against HPV is in development, there is no curative treatment for genital HPV infection. Treatments are available for the abnormalities caused by HPV infection.
    [Show full text]
  • HPV, Anal Dysplasia and Anal Cancer
    HPV, anal dysplasia FACT and anal cancer SHEET Published 2016 Summary Anal cancer typically develops over a period of years, beginning with a precancerous condition called anal dysplasia. CONTACT US Anal dysplasia occurs when clusters of abnormal cells form by telephone lesions in the mucosa lining of the anal canal (between the 1-800-263-1638 anus and the rectum). The lesions typically form inside the anal 416-203-7122 canal or just outside the anal opening. by fax 416-203-8284 Although there are over 100 different types of the human papillomavirus (HPV), anal dysplasia is usually caused by certain by e-mail strains of HPV which can be transmitted sexually. HPV can shut [email protected] off the proteins that help prevent dysplasia and cancer cells from developing, therefore leading to HPV-associated diseases by mail such as anal dysplasia. 555 Richmond Street West Suite 505, Box 1104 It is difficult to screen for anal dysplasia since the lesions are Toronto ON M5V 3B1 not detectable by routine examinations. As a result, anal dysplasia is often not detected until it has developed into anal cancer, which can be difficult to treat depending on the severity. Specific screening tests can detect dysplasia or precancerous changes. If these precancers are treated, anal cancer may be prevented. Anal cancer is usually treated with radiation and chemotherapy or with surgery. Although anal dysplasia may be treated successfully, individuals with HIV are at increased risk of it recurring and may need to be monitored closely by a trained physician. Consistent condom use reduces, but does not eliminate, the risk of transmitting HPV.
    [Show full text]
  • HPV and Cervical Cancer, Screening and Prevention
    HPV and Cervical Cancer, Screening and Prevention John Ragsdale, MD July 12, 2018 CME Lecture Series We have come a long Way… Prevalence HPV in Young Adults in U.S HPV genotypes • 20% of all • 55-60% of adeno- All cancers carcinomas 16 18 The 6,11 rest • 90-95% of • 25% all warts cervical cancers HPV Vaccines • Gardisil 9: – 6, 11, 16, 18, 31, 33, 45, 52, and 58 • Gardisil: – 6, 11, 16, and 18 • Cervarix: – 16 & 18 – For girls only How Effective is the HPV vaccine? • Answer – very!!! • Large RCT of 2392 women ages 16-23 split into two groups. All women were tested for HPV virus at enrollment – One group was placebo • Rate of persistent HPV infection 3.8% – One group got series of 3 HPV 16 vaccines at 0,2,and 6 months • Rate of persistent infection 0% A controlled trial of a human papillomavirus type 16 vaccine. Koutsky LA1, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU; Department of Epidemiology, University of Washington, Seattle, USA. [email protected] HPV vaccine: efficacy • HPV Cancers U.S. HPV Cancers 2008-12: 38,793 – 38,793 HPV-associated cancers (11.7 per 100,000 persons) • 23,000 (13.5) among females 15,793 • 15,793 (9.7) among males. 23,000 – 30,700/38,793 = HPV attributed – 28,500/38793 = Preventable Women Men Human Papillomavirus–Associated Cancers — United States, 2008–2012 MMRW Weekly / July 8, 2016 / 65(26);661–666 74% Preventable Risk Factors Cervical Cancer Screening Being rarely or never screened is THE major contributing factor to the MOST cervical cancer deaths today.
    [Show full text]
  • Cytological Changes Preceding Cervical Cancer
    27828 Clin Pathol 1994;47:278-279 Cytological changes preceding cervical cancer J H Robertson, B Woodend, H Elliott J Clin Pathol: first published as 10.1136/jcp.47.3.278 on 1 March 1994. Downloaded from Abstract invasive disease. However, recent studies of Cervical smears were reviewed from 62 cervical intraepithelial neoplasia (CIN), the women who developed squamous carci- histological counterpart of dyskaryosis, cast noma of the cervix up to 18 years later. doubt on this concept of the evolution of The findings indicate that the prevention cancer. 1 of cervical cancer by screening depends To investigate the relation between carci- very largely on the detection of severe noma and dyskaryosis we report a study dyskaryosis. In this series there was no based on 62 women with cervical cancer, evidence that mild dyskaryosis was a describing the cytology of positive smears forerunner of invasive disease. Cytology taken up to 18 years before diagnosis of the during the evolution of squamous disease. carcinoma is not characterised by a dyskaryosis which progressively in- creases in severity. Instead the findings Methods support new concepts that cervical can- Most of these 62 patients had been given cer generally arises from an aggressive false negative smear reports by a number of CIN 3 lesion widely present in the cervix, laboratories at varying intervals before the and in our series, established years development of carcinoma. The method of before invasion occurs. It would be more tracing the patients and their smears has been useful to report cytology as showing described before.3 The present study also either a low or high grade abnormality includes patients who had positive smear rather than distinguishing between dif- reports but who were lost to follow up and ferent degrees of dyskaryosis.
    [Show full text]
  • Anal Cancer, HIV, and Gay
    treatment ISSUES SEPTEMBER09 Treatment AnalISSUES cancer, HIV, and gay/bisexual men By Liz Margolies, LCSW, and Bill Goeren, LCSW In the general population, anal cancer is a rare disease. has decreased overall mortality from HIV, it has not Few people knew about it before Farrah Fawcett made reduced the incidence of anal squamous cell carcinoma public her struggle with the illness. Among men who (SCC).4 And, since it is spread through sexual skin-to- have sex with men (MSM), and especially HIV-positive skin contact, condom use only partially reduces the risk MSM, the incidence of anal cancer is significantly more of transmission. Other factors that increase the risk of prevalent and increasing annually.1 However, the major- anal cancer include a high number of sex partners, and ity of gay and bisexual men know little about the use of alcohol, drugs and tobacco. Although many men disease, have never been tested for it, nor know that have no obvious symptoms, one of the most common screening tests exit. Health care professionals, too, manifestations of HPV infection is genital warts which remain divided on how and whether to screen for it. In can affect the anus, the penis and/or the peritoneum, a fact, a standardized screening protocol for anal cancer does not yet exist. HIV-positive MSM are 40 times Each year anal cancer is diagnosed in about two peo- more likely to be diagnosed ple out of every 100,000 people in the general popula- with anal cancer. tion. HIV negative MSM are 20 times more likely to be diagnosed with anal cancer.
    [Show full text]
  • Recommendations for Cervical Cytology Terminology
    DOI:10.1111/j.1365-2303.2007.00469.x European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology A. Herbert*, C. Bergeron , H. Wienerà, U. Schenck§, P. Klinkhamer–, J. Bulten** and M. Arbyn *GuyÕs & St ThomasÕ Hospital NHS Foundation Trust, London, UK, Laboratoire Pasteur Cerba, Cergy Pontoise, France, àInstitute of Clinical Pathology, University Vienna, Vienna, Austria, §Institute of Pathology, Technical University Munich, Munich, Germany, –PAMM, Eindhoven, The Netherlands, **Institute of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands and Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium Accepted for publication 20 April 2007 A. Herbert, C. Bergeron, H. Wiener, U. Schenck, P. Klinkhamer, J. Bulten and M. Arbyn European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology There are many different systems of cytology classification used in the member states of the European Union (EU) and many different languages. The following short annexe to Chapter 3 of the European Guidelines for Quality Assurance in Cervical Cancer Screening provides a framework that will allow different terminologies and languages to be translated into standard terminology based on the Bethesda system (TBS) for cytology while retaining the cervical intraepithelial neoplasia (CIN) classification for histology. This approach has followed extensive consultation with representatives of many countries and professional groups as well as a discussion forum published in Cytopathology (2005;16:113). This article will describe the reporting of specimen adequacy, which is dealt with in more detail elsewhere in Chapter 3 of the guidelines, the optional general categorization recommended in TBS, the interpretation ⁄ cytology result and other comments that may be made on reports such as concurrent human papillomavirus testing and the use of automation review and recommendations for management.
    [Show full text]
  • Abnormal Pap Smears: Management and Counseling
    Abnormal Pap Smears: Faculty Management and Seshu P. Sarma, M.D. Counseling Emory Regional Training Center Satellite Conference and Live Webcast Atlanta, Georgia Wednesday, February 14, 2007 2:00 - 4:00 p.m. (Central Time) Produced by the Alabama Department of Public Health Video Communications and Distance Learning Division Program Objectives Program Objectives • Discuss the epidemiology and • Describe Bethesda 2001 Pap etiology of cervical precancerous terminology. and cancerous disease. • Describe the natural course of HPV • Discuss management guidelines for infection and its role in the development of cervical cancer. various abnormal Pap smear findings. • Discuss new Pap smear recommendations and the rationale behind the new changes. Cervical Cancer Etiology of Cervical Cancer • Incidence of Cervical Cancer: • Infection with high risk HPV – 9.2 per 100,000 (age-adjusted for the US population) in 2000 – 16,18,31,33,35,39,45,51,52,56,58,59 and 68 • Cervical cancer incidence has decreased by 77.7% from 1950 to – Mostly 16,18,45 and 31 2001 • Mortality reduced by as much as 70% – Due to pap smear screening 1 HPV Infection HPV and Cervical Cancer • The prevalence of genital HPV • HPV infections resolve infection spontaneously within 1-2 years. • Persistent infection with High Risk – Highest among sexually active HPV infection is a prerequisite for teens and women in their 20s the development of cervical cancer. • Although HPV infection is necessary – Decreases after age 30 for the development of cervical cancer, majority of women who
    [Show full text]
  • Exploring Anal Self-Examination As a Screening Tool for Women at Risk for Anal Cancer: Awareness, Interest, and Barriers to Beha
    Cancer Causes & Control (2019) 30:559–568 https://doi.org/10.1007/s10552-019-01175-1 ORIGINAL PAPER Exploring anal self‑examination as a screening tool for women at risk for anal cancer: awareness, interest, and barriers to behavioral uptake David A. Moskowitz1,2 · Musarrat Rahman3 · Dennis H. Li1,2 Received: 4 October 2018 / Accepted: 24 April 2019 / Published online: 29 April 2019 © Springer Nature Switzerland AG 2019 Abstract Purpose Anal cancer is the second most common human-papillomavirus-related cancer in women, with women also at an elevated risk of incidence relative to men. Anal self-examination (ASE) is an efcient way for women to screen between provider visits for potential anal masses. While studied in male populations, no research has explored women’s awareness of the self-test. Methods In response, 345 women recruited from online advertisements and listservs were surveyed to assess their experi- ences using health care, history of Pap smears, knowledge of anal cancer, awareness and attitudes surrounding ASEs, and potential educational modalities to promote ASE enactment. Results Results indicated the sample failed two key anal cancer knowledge tests (receiving a 68%/100% for risk factors and 61%/100% for signs/symptoms), and only 2.3% of participants had ever heard of ASEs before the survey. Most thought ASEs would be somewhat helpful as a screening tool, but little interest was shown towards future performance. Analyses revealed this disinterest was due to lack of knowledge, perceived discomfort with performing ASEs, and perceived irrelevance of ASEs. Conclusions Future interventions should push for a stronger role of providers (e.g., gynecologists) in anal health, education, and screening.
    [Show full text]
  • Essentials of Pap Smear and Breast Cytology
    Essentials of Pap Smear and Breast Cytology Brenda Smith Gia-Khanh Nguyen 2012 Essentials of Pap Smear and Breast Cytology Brenda Smith, BSc, RT, CT (ASCP) Clinical Instructor Department of Pathology & Laboratory Medicine University of British Columbia Vancouver, British Columbia, Canada And Gia-Khanh Nguyen, MD, FRCPC Professor Emeritus Department of Laboratory Medicine & Pathology University of Alberta Edmonton, Alberta, Canada All rights reserved. Legally deposited at Library and Archives Canada. ISBN: 978-0- 9780929-7-9. 2 Table of contents Preface 4 Acknowledgements and Related material by the same author 5 Abbreviations and Remarks 6 Chapter 1. Pap smear: An overview 7 Chapter 2. Pap smear: Normal uterus and vagina 18 Chapter 3. Pap smear: Negative for intraepithelial lesion or malignancy: Infections and nonneoplastic findings 28 Chapter 4. Pap smear: Squamous cell abnormalities 51 Chapter 5. Pap smear: Glandular cell abnormalities 69 Chapter 6. Pap smear: Other malignant tumors 90 Chapter 7. Anal Pap smear: Anal-rectal cytology 98 Chapter 8. Breast cytology: An overview 102 Chapter 9. Nonneoplastic breast lesions 106 Chapter10. Breast neoplasms 116 The authors 146 3 Preface This monograph “Essentials of Pap Smear and Breast Cytology” is prepared at the request of a large number of students in cytology who wish to have a small and concise book with numerous illustrations for easy reference during their laboratory training. Most information and illustrations in this book are extracted from the authors’ monograph entitled “Essentials of Gynecologic Cytology”, and they are rearranged according to The Bethesda System-2001. This book should be used in conjunction with the above-mentioned book on gynecologic cytology.
    [Show full text]
  • HIV in Sexual and Gender Minority Populations
    © National HIV Curriculum PDF created September 30, 2021, 7:20 am HIV in Sexual and Gender Minority Populations This is a PDF version of the following document: Module 6: Key Populations Lesson 7: HIV in Sexual and Gender Minority Populations You can always find the most up to date version of this document at https://www.hiv.uw.edu/go/key-populations/hiv-sexual-gender-minority-populations/core-concept/all. Background Defining Sexual and Gender Minority Populations Sexual identity and gender identity are highly personal to each individual. It is important to understand that sexual orientation and gender identity are distinct concepts: sexual orientation describes who a person feels romantic or sexual attraction toward, whereas gender identity is a person’s innermost sense of gender or self, which does not necessarily correspond with a person's assigned sex at birth. The term “sexual minorities” typically refers to individuals who identify as lesbian, gay, bisexual, or any other non-heterosexual identity, whereas the term “gender minorities” refers to individuals who have gender identities that are not associated with their birth sex. Increasingly, there is recognition that self-identification of gender can be nonbinary, with some individuals experiencing a gender identity that is outside the categories of man or woman. Sexual and gender minorities may include lesbian, gay, bisexual, transgender queer, intersex, and asexual (LGBTQIA) individuals, as well as others. Most available epidemiologic and medical literature has focused on lesbian, gay, bisexual, and transgender (LGBT) persons. This review on sexual and gender minority persons will focus on issues related to living with HIV, risk for acquiring HIV, and general health.
    [Show full text]